

Bod commences Phase I Clinical trial

- In a major milestone, Phase I Clinical Trial of Bod's unique 'Cannabis Wafer Product' has been approved by the Australian Government's Therapeutic Goods Administration (TGA)
- All trial subjects identified - first patient visit commences immediately effective of 24 July 2018
- Cannabis Wafer Product is the unique combination of a proprietary phytocomplex cannabis extract sourced from Swiss pharmaceutical company, Linnea which is suspended in iX Biopharma's unique patented sublingual wafer
- Objective of Phase I Clinical trial is to test the safety and tolerability of the finished product - Bod to retain 100% ownership of all global rights and IP
- Post completion of the Phase I, focus will shift to testing for globally significant, specific indications for the finished product including chemotherapy-associated nausea and vomiting, Multiple Sclerosis, Epilepsy, anti-inflammation treatment and anxiety
- Bod actively pursuing licencing and partnership agreements with leading institutions as trial process progresses - partnerships to assist in subsidising trial costs
- Licencing and partnerships agreements to potentially assist the Company in gaining access to global export market opportunities

Sydney, Australia – 24 July 2018: Developer and distributor of natural, evidence-based skincare and health supplements, Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise it has commenced its Phase I Clinical trial to test the safety, tolerability and pharmacokinetics of Bod's proprietary phytocomplex cannabis extract (ECs315) suspended in a sublingual wafer.

Bod has recently completed a number of pivotal steps towards the commencement, including trial site initiation, product formulation of the trial-ready product, patient recruitment and screening processes and gaining regulatory approvals from the Therapeutic Goods Administration.

The Company advises that first patient visits will commence effective of 24 July 2018. This process involves trial subjects receiving initial doses of the Company's proprietary phytocomplex cannabis ECs315 extract. Following this phase, a second trial segment will begin in August. Bod expects its Phase I Clinical trial to be completed by November 2018.

Pending success in the trial, the Company will have access to a unique, standardised, reproducible and patent protected cannabis product which can be sold domestically, internationally or licenced to large scale pharmaceutical companies. Bod is exploring multiple opportunities around the sale, export and licencing of this cannabis product and will update the market as these initiatives progress.

Further, the Company will move towards Phase 2 Clinical trials, in which the product will be evaluated for specific indications such as chemotherapy-associated nausea and vomiting, Multiple Sclerosis, Epilepsy, anti-inflammation treatment and anxiety.

Bod Australia CEO Jo Patterson said: “We are thrilled to have commenced our Phase I Clinical trial to test our proprietary phytocomplex cannabis extract ECs315 and unique patented delivery method.

“The Company has achieved a number of milestones to date, including product formulation, patient recruitment and granting of all necessary regulatory approvals, and look forward to first patient visits today.

“As the trial progresses, Bod will continue to explore ways in which we can leverage our cannabis product innovations through partnerships and collaborations with key researchers. Further, the Company will continue to progress opportunities to sell, licence and distribute our finished sublingual wafer product.

“We look forward to updating the market on these developments and progress with the Company’s Phase I Clinical trial in the coming weeks.”

For more information: bodaustralia.com

- ENDS -

About Bod Australia

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics, natural medicines and health supplements, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 900 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia has also build a multi-faceted cannabis business underpinned by a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions and an exclusive licence and manufacturing agreement with Singapore listed company iX Biopharma. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson

Bod Australia

+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538